.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
Boehringer Ingelheim
US Army
Harvard Business School
Daiichi Sankyo
QuintilesIMS
Medtronic
Cipla
Covington

Generated: July 21, 2017

DrugPatentWatch Database Preview

CATAPRES-TTS-2 Drug Profile

« Back to Dashboard

Which patents cover Catapres-tts-2, and what generic Catapres-tts-2 alternatives are available?

Catapres-tts-2 is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in CATAPRES-TTS-2 is clonidine. There are twenty-one drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the clonidine profile page.

Summary for Tradename: CATAPRES-TTS-2

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list35
Clinical Trials: see list31
Patent Applications: see list6,600
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CATAPRES-TTS-2 at DailyMed

Pharmacology for Tradename: CATAPRES-TTS-2

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
CATAPRES-TTS-2
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-002Oct 10, 1984ABRXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CATAPRES-TTS-2

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
CATAPRES-TTS-2
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-002Oct 10, 19844,559,222► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-2
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-002Oct 10, 19843,454,701► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-2
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-002Oct 10, 19844,060,084► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-2
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-002Oct 10, 19844,201,211► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-2
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-002Oct 10, 19843,996,934► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Johnson and Johnson
Cantor Fitzgerald
AstraZeneca
Chinese Patent Office
Fuji
Queensland Health
Dow
Novartis
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot